New study examines belantamab combos for myeloma relapse

NCT ID NCT07637526

Not yet recruiting Knowledge-focused Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will review medical records of about 100 adults with multiple myeloma that has returned after initial treatment. Researchers want to see how well belantamab mafodotin given with other drugs (bortezomib and dexamethasone, or pomalidomide and dexamethasone) works in real-world, compassionate-use settings. The goal is to gather information on patient characteristics, treatment patterns, and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin combined with bortezomib and dexamethasone, or with pomalidomide and dexamethasone
What this could lead to: If successful, this study could provide real-world evidence on how well these drug combinations work for multiple myeloma that has returned after initial treatment.
What could go wrong: This is a small, retrospective observational study, not a controlled trial. It cannot prove cause and effect, and results may not apply to all patients. There is also a risk of side effects from the drugs, such as eye problems or low blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSE MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSE MULTIPLE MYELOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.